On World Duchenne Awareness Day, Duchenne UK and Aparito announce a new study to help validate a new approach, the DMDhome digital platform, to testing drugs in clinical trials.

The DMDhome platform is the result of a successful collaboration between Duchenne UK and Aparito which uses video capture and computer vision analysis to measure limb function in Duchenne muscular dystrophy (DMD). The study will aim to validate this new approach for use in clinical trials and potentially in the approval of new medicines for DMD.

Read more here